Information Provided By: 
Fly News Breaks for April 27, 2017
CNMD
Apr 27, 2017 | 08:45 EDT
Needham analyst Mike Matson raised his price target for CONMED to $54 from $48 after the company's Q1 revenue and EPS beat consensus and management maintained its 2017 guidance. The analyst is encouraged by the improvement in revenue growth and reiterates a Buy rating, though he needs to see it sustained for a few more quarters before he is comfortable declaring the CONMED turnaround a success.
News For CNMD From the Last 2 Days
CNMD
Apr 24, 2024 | 18:48 EDT
Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGSImpinj (PI) up... To see the rest of the story go to thefly.com. See Story Here
CNMD
Apr 24, 2024 | 16:07 EDT
CNMD
Apr 24, 2024 | 16:05 EDT
CNMD
Apr 24, 2024 | 16:04 EDT
Reports Q1 revenue $312.3M, consensus $306.78M. "2024 is off to a solid start as the quarter delivered our expected top- and bottom-line growth and margin expansion," commented Curt R. Hartman, CONMED's Chair of the Board, President, and Chief Executive Officer. "We remain well positioned with a compelling and diverse portfolio to drive continued growth across the markets we serve."
